MEDI MIX M300 by Meditech is a pharmaceutical-grade dual-ester Drostanolone blend combining Drostanolone Propionate and Drostanolone Enanthate in a single oil-based injectable formulation at 300 mg/mL. The combination of a short-acting and a long-acting ester of the same base compound represents a pharmacokinetically intentional dual-phase release strategy, documented in anabolic research literature for its capacity to deliver both rapid-onset and sustained drostanolone activity within a single administration.
 
✔ Key Research Insights
Studied for its dual-phase pharmacokinetic profile, with drostanolone propionate contributing rapid-onset anabolic availability and drostanolone enanthate providing prolonged sustained release in research subjects
Investigated for drostanolone's DHT-derived pharmacological profile, including its documented SHBG binding affinity, anti-estrogenic properties, and absence of aromatization in comparative steroid pharmacology research
Researched for its effects on muscle density and vascular parameters in clinical observations, attributed to drostanolone's structural characteristics and non-estrogenic activity profile
Examined for its influence on lean mass preservation during caloric deficit protocols in documented subject populations, a pharmacological characteristic frequently associated with drostanolone across anabolic research literature
Documented for its absence of water retention and estrogenic activity across both constituent ester forms, associated with a dry anabolic profile in comparative steroid research
Manufactured by Meditech to pharmaceutical-grade purity and precision blending standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: MEDI MIX M300
Molecules:
Drostanolone Propionate: 100 mg/mL
Drostanolone Enanthate: 200 mg/mL
Total Concentration: 300 mg/mL
Appearance: Oil-based solution
Packing: Sterile 10 mL clear glass vial with red flip-off cap and labeled box
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
MEDI MIX M300 delivers two ester-modified forms of drostanolone simultaneously via intramuscular injection, each undergoing enzymatic hydrolysis at a distinct rate to release free drostanolone into systemic circulation across a staggered dual-phase timeline in research subjects. Drostanolone propionate, as the shorter-acting ester, undergoes relatively rapid hydrolysis following administration, producing an early elevation of circulating drostanolone and establishing pharmacological activity within a compressed timeframe. Drostanolone enanthate, as the longer-acting ester, undergoes gradual hydrolysis over an extended period, maintaining sustained serum drostanolone concentrations across a prolonged inter-dose interval. Drostanolone itself is a 2α-methyl-dihydrotestosterone derivative that does not undergo aromatization to estrogen, a structural characteristic associated in research literature with the absence of estrogen-related effects including fluid retention. Its high binding affinity for sex hormone-binding globulin (SHBG) has been documented in pharmacological research as a mechanism associated with increased free androgen availability in subject populations. Effects on muscle density, nitrogen retention, and protein synthesis have been investigated across documented anabolic research protocols, with lean mass preservation during caloric deficit conditions representing a particularly noted area of clinical research interest for this compound class.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and precision blending standards
Dual-ester exclusive drostanolone formulation combining short- and long-acting release profiles within a single 300 mg/mL injectable solution
Non-aromatizing DHT-derived compound with a well-documented absence of estrogenic activity across both constituent ester forms in comparative steroid pharmacology research
Supplied in a clearly labeled sterile glass vial with secure flip-off cap, consistent with pharmaceutical packaging standards
Widely referenced in anabolic pharmacology research under the drostanolone propionate, drostanolone enanthate, and Masteron designations